Published in Antimicrob Agents Chemother on November 01, 1997
Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (1998) 1.92
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev (2008) 1.26
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother (2000) 1.26
Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother (2000) 1.17
In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother (2002) 0.98
Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother (2005) 0.92
Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrob Agents Chemother (2000) 0.83
New Drugs for the Treatment of HIV Infection. Curr Infect Dis Rep (2001) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science (1995) 18.40
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 10.13
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
HIV-1 protease inhibitors. A review for clinicians. JAMA (1997) 4.34
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med (1996) 3.35
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A (1995) 3.18
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother (1995) 2.21
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS (1996) 2.14
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother (1996) 2.13
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis (1991) 1.93
Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother (1993) 1.88
In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res (1996) 1.56
Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS (1995) 1.55
Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother (1997) 1.53
Multiple drug effect analysis with confidence interval. Antiviral Res (1994) 1.26
Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother (1992) 1.25
Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem (1996) 1.24
Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides. Mol Pharmacol (1994) 1.24
Rational approaches to resistance: using saquinavir. AIDS (1996) 1.13
Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res (1996) 1.04
Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother (1996) 1.03
Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother (1994) 0.92
Hydroxyurea increases the phosphorylation of 3'-fluorothymidine and 3'-azidothymidine in CEM cells. Eur J Biochem (1989) 0.90
Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci U S A (1994) 0.89
Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res (1996) 0.85
Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Antiviral Res (1997) 0.82
Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature (1994) 5.12
Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res (2001) 3.24
Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol (2001) 2.28
Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res (1998) 1.65
Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother (1997) 1.53
Vascular effects following homozygous disruption of p47(phox) : An essential component of NADPH oxidase. Circulation (2000) 1.48
Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res (1999) 1.31
p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler Thromb Vasc Biol (2004) 1.26
Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol (2001) 1.22
Upregulation of p67(phox) and gp91(phox) in aortas from angiotensin II-infused mice. Am J Physiol Heart Circ Physiol (2000) 1.21
Role of superoxide in apoptosis induced by growth factor withdrawal. Am J Physiol (1998) 1.09
Oxidative stress increases glyceraldehyde-3-phosphate dehydrogenase mRNA levels in isolated rabbit aorta. Am J Physiol (1996) 1.04
Paracrine role of adventitial superoxide anion in mediating spontaneous tone of the isolated rat aorta in angiotensin II-induced hypertension. Hypertension (1999) 1.01
NADPH oxidase-derived ROS and the regulation of pulmonary vessel tone. Am J Physiol Heart Circ Physiol (2012) 0.99
Expression of prostaglandin H2-mediated mechanism of vascular contraction in hypertensive rats. Relation to lipoxygenase and prostacyclin synthase activities. Circ Res (1994) 0.96
Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother (1994) 0.92
Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Antiviral Res (1997) 0.82
Ocular effects of a novel cytochrome P-450-dependent arachidonic acid metabolite. Invest Ophthalmol Vis Sci (1989) 0.81
Vascular gp91(phox): beyond the endothelium. Circ Res (2000) 0.81
Immunochemical studies on the contribution of NADPH cytochrome P-450 reductase to the cytochrome P-450-dependent metabolism of arachidonic acid. Arch Biochem Biophys (1987) 0.80
The interdependence of dentist and laboratory in successful management of a rehabilitation case. Part 1. J Dent Technol (2001) 0.75
Differential responses of pituitary kallikrein and prolactin to tamoxifen and chlorotrianisene. Mol Cell Endocrinol (1989) 0.75